ReviewFrontiers in oncology2023
Effect of radiotherapy interruption on nasopharyngeal cancer.
Review in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Comparing the effectiveness of various cumulative doses of cisplatin in treating locally advanced nasopharyngeal cancer during the period of intensity-modulated radiotherapy: a meta-analysis.Frontiers in medicine · 2026Pooled it
- Multidisciplinary Team Support for Patients With Head and Neck Cancer Receiving Radiotherapy: A Randomized Clinical Trial.JAMA network open · 2025Trial
- Complementary roles of GPU-accelerated Monte Carlo and ArcCHECK in TomoTherapy quality assurance.Physical and engineering sciences in medicine · 2026Article
- Quality and dissemination of nasopharyngeal cancer health information on TikTok and Bilibili: Cross-sectional study.Medicine · 2026Article
- Precision management of radiotherapy interruption in locoregionally advanced nasopharyngeal carcinoma: Induction chemotherapy counteracts the survival impact in high-risk patients defined by a novel model.Translational oncology · 2026Article
- Time toxicity in CBCT-guided radiation therapy: A retrospective analysis of unplanned imaging burden across disease sites.Technical innovations & patient support in radiation oncology · 2026Article
- Salvigenin: a natural ally against nasopharyngeal carcinoma's malignant phenotypes and immune evasion.Journal of molecular histology · 2025Article
- [Progress of scRNA-seq technology in nasopharyngeal carcinoma research].Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery · 2025Review
- Article
- Factors Associated With Early Discontinuation of Radiation Therapy: An Analysis of the National Cancer Database.Advances in radiation oncology · 2025Article
- The role of radiotherapy in distant nasopharyngeal carcinoma: a SEER analysis.Translational cancer research · 2025Article
- Comparison of treatment outcomes between combined chemotherapy-radiation therapy (chemo-RT) and radiation therapy alone (RT) for intracranial germ cell tumors in adolescent and young adult patients (AYA).Discover oncology · 2025Article
- Recent advances in nanomedicine design strategies for targeting subcellular structures.iScience · 2025Review
- Analysis of reasons and risk factors for non-completion of radiotherapy courses in patients with tumors.Frontiers in oncology · 2025Article
- The IL-10/STAT3 Axis Nasopharyngeal Carcinoma Cancer stem cell and radio resistance.Scientific reports · 2024Article
- Influence of radiotherapy interruption on esophageal cancer with intensity-modulated radiotherapy: a retrospective study.BMC cancer · 2024Article
- Management and outcomes of breast cancer patients with radiotherapy interruption.Frontiers in oncology · 2024Article
- Development of A Nomogram for Progression-free Survival in Patients with Stage II/T3N0 Nasopharyngeal Carcinoma to Explore Different Treatment Modalities.Journal of Cancer · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nasopharyngeal carcinoma (NPC) is a malignant tumor originating from the epithelial cells of the nasopharynx with a unique geographic distribution, and is particularly prevalent in East and Southeast Asia. Due to its anatomical location, the surgery is difficult to access and the high sensitivity of nasopharyngeal cancer to radiotherapy (RT) makes it the main treatment modality. Radical radiotherapy is the first-line treatment for early-stage nasopharyngeal carcinoma and the cornerstone of multidisciplinary treatment for patients with locally advanced nasopharyngeal carcinoma. Nevertheless, radiotherapy interruption is inevitable as a consequence of unavoidable factors such as public holidays, machine malfunction, patient compliance, and adverse response to treatment, which in turn leads to a reduction in bioactivity and causes sublethal loss of tumor cells to repair. Unirradiated tumor cells are more likely to repopulate at or near their original fastest growth rate during this interval. If no measures are taken after the radiotherapy interruption, such as increasing the dose of radiotherapy and systemic therapy, the tumor is most likely to go uncontrolled and then progress. This review describes the effects of radiotherapy interruption on nasopharyngeal carcinoma, the mechanism of the effect, and explores the measures that can be taken in response to such interruption.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.